Published in Oncotarget on April 19, 2017
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity (1995) 5.77
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell (1992) 5.53
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med (2016) 4.33
In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol Cell (2000) 4.10
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 4.08
Cbl-b regulates the CD28 dependence of T-cell activation. Nature (2000) 3.89
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med (2003) 3.21
Molecular basis of T cell inactivation by CTLA-4. Science (1998) 3.00
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett (2004) 2.77
c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol (2002) 2.64
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 2.58
CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J Immunol (2003) 2.32
Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol (2005) 2.31
Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal (2012) 2.24
Scaffold protein Dlgh1 coordinates alternative p38 kinase activation, directing T cell receptor signals toward NFAT but not NF-kappaB transcription factors. Nat Immunol (2006) 2.13
Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol (2001) 2.02
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science (1996) 1.99
T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J (2006) 1.92
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol (2013) 1.79
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med (2011) 1.77
GRB2 and phospholipase C-gamma 1 associate with a 36- to 38-kilodalton phosphotyrosine protein after T-cell receptor stimulation. Mol Cell Biol (1994) 1.71
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol (2016) 1.70
CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J Immunol (2001) 1.61
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science (2017) 1.58
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science (2017) 1.58
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun (2015) 1.36
T cell replicative senescence in human aging. Curr Pharm Des (2013) 1.31
K33-linked polyubiquitination of T cell receptor-zeta regulates proteolysis-independent T cell signaling. Immunity (2010) 1.30
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell (2015) 1.27
PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med (2011) 1.27
PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle (2012) 1.12
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol Cell Biol (2013) 0.99
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov (2016) 0.98
Cbl-b regulates antigen-induced TCR down-regulation and IFN-gamma production by effector CD8 T cells without affecting functional avidity. J Immunol (2007) 0.95
Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther (2014) 0.93
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget (2014) 0.92
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest (2016) 0.89
Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. Oncotarget (2015) 0.88
Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer. Clin Dev Immunol (2012) 0.88
PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res (2016) 0.86
Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology (2009) 0.86
PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy. Oncoimmunology (2012) 0.86
Correlation between disease activity and T-cell CD3 zeta chain expression in a B-cell lymphoma. Br J Haematol (1994) 0.83
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology (2014) 0.82
Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity. Immunity (2016) 0.82
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunol Res (2016) 0.80
Novel immunotherapies for the treatment of melanoma. Immunotherapy (2016) 0.76
A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. Oncotarget (2015) 0.75